In a separate 2 year double blinded, placebo-controlled study, weekly subcutaneous injections of semaglutide (2.4mg) in obese patients, average body weights decreased 12.6% over placebo at the 2-year point [23]
Jimnez-Jimnez, Flix Javier, et al
Cases with inaccurate or missing data and ADE start dates preceding the medication start date were excluded from the analysis
Wegovy, on the other hand, follows a similar titration schedule, with a maintenance dosage of 2.4 mg per week
Prescribing anti obesity medication without acknowledging hormonal context risks treating only half the equation
La raction se droulant dans un systme biphasique, la vitesse d'hydrolyse dpend non seulement de la quantit de substrat prsent dans le milieu mais galement de l'aire interfaciale